BMY/CELG's Multiple Myeloma (MM) sophisticated strategy for continued category dominance as Revlimid and Pomalyst go through a gradual LOE process over several years involves many different therapeutics platforms.
The original vision was articulated during CELG's Multiple Myeloma Deep Dive on 24May2018:
The JPM2021 slide reflects a more current visual of the approach:
A variety of key milestones across 2021 and 2022-23 reflect the diversity of approaches across CELMoDs (Iberdomide/CC-220, CC-92480), BCMA CAR-T 9IDE-CEL/BB2121), BCMA T-cell Engagers (CC-93269 TCE) across multiple lines of MM therapy.